172 related articles for article (PubMed ID: 30305449)
21. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.
Davies A; Merli F; Mihaljević B; Mercadal S; Siritanaratkul N; Solal-Céligny P; Boehnke A; Berge C; Genevray M; Zharkov A; Dixon M; Brewster M; Barrett M; MacDonald D
Lancet Haematol; 2017 Jun; 4(6):e272-e282. PubMed ID: 28476440
[TBL] [Abstract][Full Text] [Related]
22. Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome.
Miyabe Y; Takei T; Iwabuchi Y; Moriyama T; Nitta K
Clin Exp Nephrol; 2016 Feb; 20(1):103-10. PubMed ID: 26138356
[TBL] [Abstract][Full Text] [Related]
23. Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS).
Gottesman MH; Friedman-Urevich S
Mult Scler; 2006 Jun; 12(3):271-80. PubMed ID: 16764339
[TBL] [Abstract][Full Text] [Related]
24. Safety and Efficacy of Rituximab: Experience of a Single Multiple Sclerosis Center.
Alldredge B; Jordan A; Imitola J; Racke MK
Clin Neuropharmacol; 2018; 41(2):56-59. PubMed ID: 29389745
[TBL] [Abstract][Full Text] [Related]
25. Low-dose intrathecal rituximab is a safe and potentially effective treatment for pediatric neuroimmunologic disorders.
Santiago JA; Babico M; Stitt G; Thomas CA; Desai S; Willard S; Swing T; Kruer MC
J Neuroimmunol; 2021 Oct; 359():577687. PubMed ID: 34364103
[TBL] [Abstract][Full Text] [Related]
26. Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study.
Cohen M; Romero G; Bas J; Ticchioni M; Rosenthal M; Lacroix R; Brunet C; Rico A; Pelletier J; Audoin B; Lebrun C
J Neurol Sci; 2017 Feb; 373():335-338. PubMed ID: 28131216
[TBL] [Abstract][Full Text] [Related]
27. Rituximab for thyroid eye disease.
Silkiss RZ; Reier A; Coleman M; Lauer SA
Ophthalmic Plast Reconstr Surg; 2010; 26(5):310-4. PubMed ID: 20562667
[TBL] [Abstract][Full Text] [Related]
28. Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).
Rommer PS; Dörner T; Freivogel K; Haas J; Kieseier BC; Kümpfel T; Paul F; Proft F; Schulze-Koops H; Schmidt E; Wiendl H; Ziemann U; Zettl UK;
J Neuroimmune Pharmacol; 2016 Mar; 11(1):1-8. PubMed ID: 26589235
[TBL] [Abstract][Full Text] [Related]
29. Intrathecal rituximab therapy in multiple sclerosis: review of evidence supporting the need for future trials.
Bonnan M; Ferrari S; Bertandeau E; Demasles S; Krim E; Miquel M; Barroso B
Curr Drug Targets; 2014; 15(13):1205-14. PubMed ID: 25355180
[TBL] [Abstract][Full Text] [Related]
30. Rituximab therapy in pemphigus: A long-term follow-up.
Loi C; Magnano M; Ravaioli GM; Sacchelli L; Patrizi A; Bardazzi F
Dermatol Ther; 2019 Jan; 32(1):e12763. PubMed ID: 30288877
[No Abstract] [Full Text] [Related]
31. [Rituximab: its efficacy, effectiveness and safety in the treatment of multiple sclerosis].
Midaglia L; Mora L; Mulero P; Sastre-Garriga J; Montalban X
Rev Neurol; 2018 Jan; 66(1):25-32. PubMed ID: 29251340
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant rituximab treatment for pemphigus: A retrospective study of 45 patients at a single center with long-term follow up.
Kim TH; Choi Y; Lee SE; Lim JM; Kim SC
J Dermatol; 2017 Jun; 44(6):615-620. PubMed ID: 28186358
[TBL] [Abstract][Full Text] [Related]
33. Rituximab for relapsing-remitting multiple sclerosis.
He D; Zhou H; Han W; Zhang S
Cochrane Database Syst Rev; 2011 Dec; (12):CD009130. PubMed ID: 22161445
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients.
Hoffmann V; Schimrigk S; Islamova S; Hellwig K; Lukas C; Brune N; Pöhlau D; Przuntek H; Müller T
J Neurol Sci; 2003 Jul; 211(1-2):81-4. PubMed ID: 12767502
[TBL] [Abstract][Full Text] [Related]
35. Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden.
McKay KA; Piehl F; Englund S; He A; Langer-Gould A; Hillert J; Frisell T
JAMA Netw Open; 2021 Dec; 4(12):e2136697. PubMed ID: 34851401
[TBL] [Abstract][Full Text] [Related]
36. Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.
Mao Z; Álvarez-González C; Allen-Philbey K; De Trane S; Yildiz O; Campion T; Adams A; Turner BP; Marta M; Gnanapavan S; Espasandin M; Mathews J; Giovannoni G; Baker D; Schmierer K
Mult Scler Relat Disord; 2019 Jan; 27():247-253. PubMed ID: 30419510
[TBL] [Abstract][Full Text] [Related]
37. Role of intrathecal rituximab and trastuzumab in the management of leptomeningeal carcinomatosis.
Perissinotti AJ; Reeves DJ
Ann Pharmacother; 2010 Oct; 44(10):1633-40. PubMed ID: 20807868
[TBL] [Abstract][Full Text] [Related]
38. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities.
Cho HH; Jin SP; Chung JH
J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):186-91. PubMed ID: 23356542
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of rituximab in multiple sclerosis: Experience from a developing country.
Mathew T; John SK; Kamath V; Murgod U; Thomas K; Baptist AA; Therambil M; Shaji A; Nadig R; Badachi S; Souza DD; Shivde S; Avati A; Sarma GRK; Sharath Kumar GG; Deepalam S; Parry GJ
Mult Scler Relat Disord; 2020 Aug; 43():102210. PubMed ID: 32485634
[TBL] [Abstract][Full Text] [Related]
40. Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis.
Nagafuchi H; Atsumi T; Hatta K; Muso E; Takeno M; Yamada H; Ozaki S
Mod Rheumatol; 2015 Jul; 25(4):603-8. PubMed ID: 25496405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
